Dopamine agonists and the risk of cardiac-valve regurgitation
Background Case reports and echocardiographic studies suggest that the ergot-derived
dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease …
dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease …
[引用][C] Dopamine agonists and the risk of cardiac-valve regurgitation
R SCHADE - N Engl J Med, 2007 - cir.nii.ac.jp
Dopamine agonists and the risk of cardiac-valve regurgitation.
SR Andersohn - New England Journal of Medicine, 2007 - aifa.gov.it
BACKGROUND: Case reports and echocardiographic studies suggest that the ergot- derived
dopamine agonists pergolide and cabergoli Page 1 New England Journal of Medicine …
dopamine agonists pergolide and cabergoli Page 1 New England Journal of Medicine …
Dopamine agonists and the risk of cardiac-valve regurgitation.
R Schade, F Andersohn, S Suissa… - The New England …, 2007 - europepmc.org
Background Case reports and echocardiographic studies suggest that the ergot-derived
dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease …
dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease …
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
R Schade, F Andersohn, S Suissa… - Obstetrical & …, 2007 - journals.lww.com
Dopamine agonists, which are first-line drugs for treating Parkinson's disease and also are
used to treat restless legs syndrome, reportedly may be associated with fibrotic heart valve …
used to treat restless legs syndrome, reportedly may be associated with fibrotic heart valve …
[PDF][PDF] Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
R Schade, F Andersohn, S Suissa, W Haverkamp… - N Engl J …, 2007 - researchgate.net
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation Page 1 The new england
journal of medicine n engl j med 356;1 www.nejm.org january 4, 2007 29 original article …
journal of medicine n engl j med 356;1 www.nejm.org january 4, 2007 29 original article …
Dopamine agonists and the risk of cardiac-valve regurgitation
R Schade, F Andersohn, S Suissa, W Haverkamp… - L'Endocrinologo, 2007 - Springer
PREMESSE: Case reports e studi ecocardiografici suggeriscono che i dopamino agonisti
derivati dell'ergot pergolide e cabergolina possono aumentare il rischio di insufficienza …
derivati dell'ergot pergolide e cabergolina possono aumentare il rischio di insufficienza …
[PDF][PDF] 1 Dopamine agonists and the risk of cardiac valve regurgitation.
R Schade, F Andersohn, S Suissa, W Haverkamp… - 1 NEJM, 2007 - rcpe.ac.uk
To investigate case reports suggesting that ergot-derived dopamine agonists, used to treat
Parkinson's disease, may increase the risk of cardiac valve regurgitation, the authors used a …
Parkinson's disease, may increase the risk of cardiac valve regurgitation, the authors used a …
[PDF][PDF] Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
R Schade, F Andersohn, S Suissa, W Haverkamp… - N Engl J Med, 2007 - Citeseer
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation Page 1 The new england
journal of medicine n engl j med 356;1 www.nejm.org january 4, 2007 29 original article …
journal of medicine n engl j med 356;1 www.nejm.org january 4, 2007 29 original article …
Dopamine agonists and the risk of cardiac-valve regurgitation
R Schade, F Andersohn, S Suissa… - The New England …, 2007 - pubmed.ncbi.nlm.nih.gov
Background Case reports and echocardiographic studies suggest that the ergot-derived
dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease …
dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease …